Target intelligence / Profile preview

Mesenchymal stem cell surface receptors

Molecular classification
Receptor, Adhesion molecule, Chemokine receptor, Cytokine receptor, Integrin, Lectin
01

Overview

Mesenchymal stem cell surface receptors are a diverse set of membrane proteins present on MSCs—cells capable of differentiating into bone, adipose, and cartilage—and known for their regenerative and immunomodulatory properties. The classical markers for MSCs include positive expression of CD105, CD73, and CD90, and lack of hematopoietic and immune markers (CD45, CD34, CD14, CD19, HLA-DR). MSCs also express functional receptors such as integrins, chemokine and cytokine receptors, adhesion molecules (e.g., ICAM-1, VCAM-1), and show tissue-specific variation in marker expression. Their surface repertoire enables them to migrate to injury sites, modulate immune responses, and participate in tissue repair, making them important in clinical applications ranging from graft versus host disease and autoimmune conditions to tissue regeneration. However, "Mesenchymal stem cell surface receptors" refers to a heterogeneous set of targets rather than a single, structurally defined molecule; specificity should be sought by focusing on individual surface receptor identities, their molecular classification, and roles in MSC biology.

Other names
MSC surface markersMSC surface proteinsstromal cell markers
02

Mechanism of action

Cell surface receptor engagement to mediate immune suppression (e.g., through ICAM-1, chemokine/cytokine receptors), trophic and paracrine signaling, and cell migration and homing to damaged tissues.

03

Biological functions

Cell adhesionSignal transductionDelineationMigrationImmune modulationHomingCell-cell communication
04

Disease associations

Regenerative medicine (e.g., orthopedic, cardiac, neurological, and immune-related indications)CancerInflammationImmune disorders (e.g., graft versus host disease, autoimmune disease)Cardiovascular disease
05

Safety considerations

Heterogeneity of MSC populations complicates therapeutic predictabilityPotential for unwanted differentiation or proliferationTumorigenicity in some contexts disputed but generally thought to be lowImmune rejection risk if not properly matched or characterized
06

Interacting drugs

The surfaceome includes some targets for cellular therapies, but there are no approved small molecules or biologic drugs directly targeting "MSC surface receptors" as a category. Cell therapies use MSCs themselves as drug products
07

Biomarkers

CD105 (Endoglin)CD73 (NT5E)CD90 (Thy-1)CD44CD166 (ALCAM)ICAM-1Other negative markers: CD45, CD34, CD14, CD19, HLA-DR

Beyond the preview

Go deeper on Mesenchymal stem cell surface receptors.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mesenchymal stem cell surface receptors.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call